Advertisement

ResearchIn-Press PreviewImmunologyOncology Open Access | 10.1172/JCI181143

An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety

Kok-Siong Chen,1 Sarah Manoury-Battais,1 Nobuhiko Kanaya,1 Ioulia Vogiatzi,1 Paulo Borges,1 Sterre J. Kruize,1 Yi-Ching Chen,1 Laura Y. Lin,1 Filippo Rossignoli,1 Natalia Claire Mendonca,1 and Khalid Shah1

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Chen, K. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Manoury-Battais, S. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Kanaya, N. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Vogiatzi, I. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Borges, P. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Kruize, S. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Chen, Y. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Lin, L. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Rossignoli, F. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Mendonca, N. in: JCI | PubMed | Google Scholar

1Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America

Find articles by Shah, K. in: JCI | PubMed | Google Scholar |

Published November 19, 2024 - More info

J Clin Invest. https://doi.org/10.1172/JCI181143.
Copyright © 2024, Chen et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 19, 2024 - Version history
View PDF
Abstract

Recent progress in cancer cell-based therapies has led to effective targeting and robust immune responses against cancer. However, the inherent safety risks of using live cancer cells necessitate the creation of an optimized safety switch without hindering the efficacy of immunotherapy. The existing safety switches typically induce tolerogenic cell death, potentially leading to an immunosuppressive tumor immune microenvironment (TIME), which is counterproductive to the goals of immunotherapy. Here, we developed and characterized an inducible RIPK3-driven necroptotic system that serves as a dual function of safety switch as well as inducing immunogenic cell death which in turn stimulates antitumor immune responses. We showed that activating RIPK3 safety switch triggered immunogenic responses marked by an increased release of adenosine triphosphate (ATP) and damage-associated molecular patterns (DAMPs). Compared to other existing safety switches, incorporating RIPK3 system inhibited tumor growth, improved survival outcomes in tumor-bearing mice, and fostered long-term antitumor immunity. Moreover, RIPK3 system reinvigorated the TIME by promoting dendritic cell (DC) maturation, polarizing the macrophages towards the M1 phenotype, and reducing the exhaustion of CD4+ and CD8+ T lymphocytes. Our study highlights the dual role of RIPK3-driven necroptotic system in improving the safety and efficacy of cancer cell-based therapy, with broader implications for cellular therapies.

Supplemental material

View Unedited blot and gel images

View

View Table S1

View Table S2

View Table S3

Version history
  • Version 1 (November 19, 2024): In-Press Preview
Advertisement
Advertisement